Best Practice & Research Clinical Anaesthesiology
Volume 24, Issue 1 , Pages 65-83 , March 2010

Platelet transfusions: the science behind safety, risks and appropriate applications

  • Bruce D. Spiess, MD, FAHA (Professor of Anesthesiology and Emergency Medicine, Director of Virginia Commonwealth University Reanimation Engineering Shock center (VCURES))

      Affiliations

    • Corresponding Author InformationTel.: +1 804-828-2267; fax: +1 804-828-6413.

References 

  1. McCullough J. 2nd edn.. Transfusion medicine. 11. Churchill, Livingston, Philadelphia, PA: Elsevier; 2005;pp. 251–308
  2. Spiess BD, Spence RK, Shander A. Perioperative transfusion medicine. 2nd edn.. Philadelphia, PA: Lippincott, Williams & Wilkins; 2006;pp. 93–102, 129–210, 645–658
  3. Ackerman SJ, Klumpp TR, Guzman GI, et al. Economic consequences of alterations in platelet transfusion dose: analysis of a prospective, randomized, double-blind trial. Transfusion. 2000;40:1457–1462
  4. Bishop JF, Schiffer CA, Aisner J, et al. Surgery in acute leukemia: a review of 167 operations in thrombocytopenic patients. American Journal of Hematology. 1987;26:147
  5. Society of Cardiovascular Anesthesiologists Special Task Force on Blood Transfusion , Spiess BD, Shore-Lesserson L, Stafford-Smith M, Mazer CD, Bennett-Guerrero E, et al. Perioperative blood transfusion and blood conservation in cardiac surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. Ann Thorac Surg. 2007;83(5 Suppl.):S27–S86
  6. Consensus Development Conference . Platelet transfusion therapy. Journal of American Medical Association. 1987;257:1777–1780
  7. Khan H, Belnher J, Yumaz M, et al. Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients. Chest. 2007;131:1308–1314
  8. Kulkarni S, Dpheide SM, Yap , et al. A revised model of platelet aggregation. The Journal of Clinical Investigation. 2000;105:783–791
  9. Hoffman M. A cell-based model of coagulation and the role of factor VIIa. Blood Reviews. 2003;1:S1–S5
  10. Hoffman M, Monroe D, Roberts H. A cell based model of hemostasis. Thrombosis and Haemostasis. 2001;85:958–965
  11. Davie EW, Ratnoff O. Waterfall sequence for intrinsic blood clotting. Science. 1964;145:1310–1312
  12. McFarlane R. A enzymatic cascade in the blood clotting mechanism, and its function as a biological amplifier. Nature. 1964;202:498–499
  13. Fredrickson BJ, Dong J, McIntire L, et al. Shear-dependent rolling on von Willebrand factor of mammalian cells expressing the platelet glycoprotein Ib-Ix-V complex. Blood. 1998;92:3684–3693
  14. Savage B, Ruggeri Z. Platelet thrombus in flowing blood. In:  Michelson A editors. Platelets. vol. 1:Amsterdam: Netherlands: Academic Press; 2002;p. 215–228
  15. Goto S, Ikeda Y, Saldivar E, et al. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions. The Journal of Clinical Investigation. 1998;101:385–392
  16. Tsai H, Sussman I, Nagel R. Shear stress enhances the proteolysis of von Willebrand's factor in normal plasma. Blood. 1994;83:2171–2179
  17. Shattil S, Hoxie J, Cunningham M, et al. Changes in platelet membrane glycoprotein IIb/IIIa complex during platelet activation. The Journal of Biological Chemistry. 1985;260
  18. Burrige K, Fath K. Focal contacts: transmembrane links between the extracellular matrix and the cytoskeleton. Bioessays. 1989;10:104–108
  19. deWit TR, Mourik JV. Biosynthesis, processing and secretion of von Willebrand factor: biological implications. Best Practice & Research. Clinical Haematology. 2001;14:241–255
  20. Monroe DM, Hoffman M, Roberts H. Platelets and thrombin generation. Arteriosclerosis, Thrombosis, and Vascular Biology. 2002;22:1381–1389
  21. Turner NA, Nolasco L, Ruggeri ZM, Moake JL. Endothelial cell ADAMTS-13 and vWF: production, release and vWF string cleavage. Blood. 2009;[E-pub PMID 19822897]
  22. Tsai H. Deficiency of ADAMTS-13 causes thrombotic thrombocytopenic purpura. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:388–396
  23. Lopez J, Andrews R, Afshar-Kharghan V, et al. Bernard-Soulier syndrome. Blood. 1998;91:4397–4418
  24. Murphy S, Heaton WA, Rebulla P. Platelet production in the Old World- and the New. Transfusion. 1996;36:751–754
  25. Vassallo RR, Murphy S. a critical comparison of platelet preparation methods. Current Opinion in Hematology. 2006;13:323–330
  26. Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Reviews. 2004;18:149–165
  27. Albanyan AM, Harrison P, Murphy MF. Markers of platelet activation and apoptosis during storage of apheresis and buff coat-activated platelet concentrates for 7 days. Transfusion. 2009;49:108–117
  28. Arnold DM, Heddle NM, Kulczyky M, et al. In vivo recovery and survival of apheresis and whole blood-derived platelets: a paired comparison in healthy volunteers. Transfusion. 2006;46:257–264
  29. Sloand Em, Yu M, Klein HG. Comparison of random-donor platelet concentrates prepared from whole blood units and platelets prepared from single-donor apheresis collections. Transfusion. 1996;36:955–959
  30. Dumont LJ, VandenBroeke T. seven-day storage of apheresis platelets: report of an in vitro study. Transfusion. 2003;43:143–150
  31. Lee CK, Ho PL, Lee KY, et al. Estimation of bacterial risk in extending the shelf life of PLT concentrates from 5 to 7 days. Transfusion. 2003;43:1047–1052
  32. Kuehnert MJ, Roth VR, Haley NR, et al. Transfusion-transmitted bacterial infection in the United States 1998–2000. Transfusion. 2001;41:1493–1499
  33. Hsueh JC, Ho CF, Chang SH, et al. Blood surveillance and detection on platelet bacterial contamination associated with septic events. Transfusion Medicine. 2009;19:E-pub
  34. Fuller AK, Uglik KM, Savage WJ, et al. Bacterial culture reduces but does not eliminate the risk of septic transfusion reactions to single donor platelets. Transfusion. 2009;E-pub
  35. Saranwong S, Ezuki S, Kawabata K, et al. A noninvasive near infrared system for detection of platelet components contaminated with bacteria. Transfusion. 2009;E-pub
  36. Rinder HM, Smith BR. In –vitro evaluation of stored platelets: is there hope for predicting post-transfusion platelet survival and function?. Transfusion. 2003;43:2–6
  37. Dumont LJ. Shake, rattle and roll. Preventing platelets from turning into Golden Oldies. Transfusion. 2008;48:2487–2489
  38. Rinder HM, Snyder EL. Activation of platelet concentrate during preparation and storage. Blood Cells. 1992;18:445–456
  39. Murphy S, Gardner FH. Platelet storage at 22°C: role of gas transport across plastic containers in maintenance of viability. Blood. 1975;46:209–218
  40. Böing AN, Hau CM, Sturk A, Nieuwland R. Platlet microparticles contain active caspase 3. Platlets. 2008;19:96–103
  41. Li J, Xa Y, Bertino AM, et al. The mechanism of apoptosis in human platelets during storage. Transfusion. 2000;40:1320–1329
  42. Caumeberghs S, vanPampus E, Curver J, et al. Haemostatic and signaling functions of transfused platelets. Transfusion Medicine Reviews. 2007;21:287–294
  43. Magdeleyns EJ, Kevren JF, Curvers J. Factor Va, bound to micro particles released during platelet storage is resistant of inactivation by activated protein C. Transfusion. 2007;47:1880–1888
  44. Hartley PS, Savill J, Brown SB. The death of human platelets during incubation in citrated plasma involves shedding of CD42b and aggregation of dead platelets. Thrombosis and Haemostasis. 2006;95:100–106
  45. Mason KD, Carpinelli MR, Fletcher JL, et al. Programmed a nuclear cell death delimits platelet life span. Cell. 2007;128:1173–1186
  46. Zaki MS, Fouda M, Shafeldeen OA, Zaghloul MH. Extracellular accumulation of bioactive substances; interleukin 1beta and plasminogen activator inhibitor-1 (PAI-1) in stored blood units and relation to bacterial contamination. Hematology. 2006;11:301–305
  47. Dineen SP, Roland CL, Toombs JE. The a cellular function of stored platelets promotes tumor cell invasion. The Journal of Surgical Research. 2009;153:132–137
  48. Bayraktroglu Z, Yiulmaz N, Cicek HK, et al. Platelet storage time and cytokine (IL-2R, IL-8, TNF- alpha) levels. Eastern Mediterranean Health Journal. 2007;13:79–84
  49. Ferrer F, Rivera J, Lozano ML, et al. Effect of cold –storage in the accumulation of bioreactive substances in platelet concentrates treated with second messenger effects. Haematologica. 2001;86:530–536
  50. Klüter H, Bubel S, Kirchner H, Wilhelm D. Febrile and allergic transfusion reactions after transfusion of white cell –poor platelet preparations. Transfusion. 1999;39:1179–1184
  51. Stilliman CC, Johnson CA, Clay KL, et al. Compounds biologically similar to platelet activating factor are present in stored blood components. Lipids. 1993;28:415–418
  52. Karasawa K, Shirakura M, Harada A, et al. Red cells highly express type 1 platelet-activating factor-acetylhydrolase (PAF-AH) which consists of the alpha1/alpha2 complex. Journal of Biochemistry. 2005;138:509–517
  53. Rubin O, Crettaz D, Canellini G, Tissot JD, Lion N. Micro particles in stored red cells: an approach using flow cytometry and proteomic tools. Vox Sanguinis. 2008;95:288–297
  54. Sadallah S, Eken C, Schifferi JA, et al. Erythrocyte cytosomes have immunosuppressive properties. Journal of Leukocyte Biology. 2008;84:1316–1325
  55. Dasqupta SK, Abdel-Monem H, Guchhait P, Nagata S, Thiagarajan P. Role of lactaherin in the clearance of phosphotidylserine expression in red blood cells. Transfusion. 2008;48:2370–2376
  56. Salzer U, Zhu R, Luten M, et al. Vesicles generated during storage of red cells are rich in the lipid raft marker stomatin. Transfusion. 2008;48:451–462
  57. Mairhofer M, Steiner M, Mosgoeller W, Prohaska R, Salzer U. Stomatin is a major lipid-raft component of platelet alpha granules. Blood. 2002;100:897–904
  58. Shamwell A, Falker C, Gulliksson H. Storage of platelets in additive solutions: the effects of magnesium and potassium on the release of RANTES, beta-thromboglobulin, platelet factor -4 and interleukin-7, during storage. Vox Sanguinis. 2003;85:206–212
  59. Terao S, Yilmaz G, Stokes KY, et al. Blood cell derived RANTES mediates cerebral microvascular dysfunction, inflammation, and tissue injury and focal ischemia-reperfusion. Stroke. 2008;39:2560–2570
  60. Dunstan RA, Simpson MB, Knowles RW, Rosse WF. The origin of ABO antigens on human platelets. Blood. 1985;65:615–619
  61. Ogasawara K, Ueki J, Takenaka M, Furihata K. Study on the expression of ABO antigens on platelets. Blood. 1993;82:993–999
  62. Murphy S. ABO blood groups and platelet transfusion. Transfusion. 1988;28:401–402
  63. Aster RH. Effect of anticoagulant and ABO incompatibility on recovery of transfused human platelets. Blood. 1965;26:732–743
  64. Duquesnoy RJ, Anderson AJ, Tomuloso PA, Aster RH. ABO compatibility and platelet transfusions of allimunized thrombocytopenic patients. Blood. 1979;54:595–599
  65. Heal JM, Blumberg N, Masel D. an evaluation of crossmatching, HLA, and ABO matching for platelet transfusions to refractory patients. Blood. 1987;70:23–30
  66. Pierce RN, Reich LM, Mayer K. Hemolysis following platelet transfusions from ABO-incompatible donors. Transfusion. 1985;25:60–62
  67. McLeod BC, Piehl MR, Sassetti RJ. Alloimmunization to RhD by platelet transfusions in autologous bone marrow transplant recipients. Vox Sanguinis. 1990;49:185–189
  68. Claas FH. Predictive parameter of in vitro alloreactivity. Transplant Immunology. 2002;10:137–142
  69. Petz LD, Garrathy G, Calhoun L, et al. Selecting donors of platelets for refractory patients on the basis of HLA antibody specificity. Transfusion. 2000;40:1446–1456
  70. Mozami N, Itescu S, Williams MR, et al. Platelet transfusions are associated with the development of anti-major histocompatibility complex class I antibodies in patients with left ventricular assist support. The Journal of Heart and Lung Transplantation. 1998;17:876–880
  71. Grossjohann B, Eichler P, Greinacher A, et al. Ceftriaxone causes drug-induced immune thrombocytopenia and hemolytic anemia characterization of targets on platelets and red blood cells. Transfusion. 2004;44:1033–1040
  72. Togna GI, Togna AR, Caprino L. Beta-lactam antibiotic-mediated changes in platelet reactivity and vascular endothelial functions. Pharmacology & Toxicology. 2001;88:277–281
  73. Shantsila E, Lip GY, Chong BH. Heparin-induced thrombocytopenia: A contemporary clinical approach to diagnosis and management. Chest. 2009;135:1651–1664
  74. Warkentin TE, Greinacher A, Koster A. Heparin-induced thrombocytopenia in patients with ventricular assist devices: are new prevention strategies required?. Annals of Thoracic Surgery. 2009;87:1633–1640
  75. Warkentin TE, Greinacher A, Koster A, Lincoff AM American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians evidence-based clinical practice (sth edition). Chest. 2008;133:340S–380S
  76. Levy JH, Tanaka KA, Hursting MJ. Reducing thrombotic complications in the perioperative setting: an update on heparin-induced thrombocytopenia. Anesthesia and Analgesia. 2007;105:570–582
  77. Hopkins CK, Goldfinger D. Platelet transfusion in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion. 2008;48:2128–2132
  78. Kleinman SH, Kamel HT, Harpool DR, et al. Two-year experience with aerobic culturing of apheresis and whole blood-derived platelets. Transfusion. 2006;46:1787–1794
  79. Yomtovian RA, Palavecino EL, Dysktra AH, et al. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital 1991- through 2004. Transfusion. 2006;46:719–730
  80. Fang CT, Chambers LA, Kennedy J, et al. Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004. Transfusion. 2005;45:1845–1852
  81. Munksgaard L, Alberg L, Lillevang ST, et al. Detection of bacterial contamination of platelet components: six years' expereince with the BacT/ALERT system. Transfusion. 2004;46:1166–1173
  82. Blumberg N, Heal JM, Liesveld JL, et al. Platelet transfusion and survival in adults with acute leukemia. Leukemia. 2008;22:631–635
  83. Khorana AA, Francis CW, Blumberg N, et al. Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Archives of Internal Medicine. 2008;168:2377–2381
  84. Stover EP, Siegel LC, Parks R, et al. Variability in transfusion practice for coronary artery bypass surgery persists despite national consensus guidelines: a 24 institution study. Anesthesiology. 1998;88:327–333
  85. Snyder-Ramos S, Mohnle P, Weng YS, et al. MCSPI Ongoing variability in transfusion practices in cardiac surgery despite established guidelines. Transfusion. 2008;48:1284–1299
  86. Mangano DT, for the Multi-Center Study of Perioperative Ischemia Research group . Aspirin and mortality from coronary bypass surgery. The New England Journal of Medicine. 2002;347:1309–1317
  87. Spiess BD, Royston D, Levy JH, et al. Platelet transfusions during coronary artery bypass graft surgery are associated with serious adverse outcomes. Transfusion. 2004;44:1143–1148
  88. Karkouti K, Wijeysundera DN, Yau TM, et al. Platelet transfusions are not associated with increased morbidity or mortality in cardiac surgery. The Canadian Journal of Anesthesia. 2006;53:279–287
  89. McGrath T, Koch CG, Xu M, et al. Platelet transfusion in cardiac surgery does not confer increased risk for adverse morbid outcomes. Annals of Thoracic Surgery. 2008;86:543–553
  90. Vamvakas EC, Carven JH. Allogeneic blood transfusion and postoperative duration of mechanical ventilation: effects of red cell supernatant, platelet supernatant, plasma components and total transfused fluid. Vox Sanguinis. 2002;82:141–149

PII: S1521-6896(09)00093-7

doi: 10.1016/j.bpa.2009.11.001

Best Practice & Research Clinical Anaesthesiology
Volume 24, Issue 1 , Pages 65-83 , March 2010

Article Tools

* Image Usage & Resolution